SS18 and synovial sarcoma: Another study showed that either Fgfr1, Fgfr2, or Fgfr3 gene knockout impeded SS18-SSX2-induced tumour formation in vivo and FGFR inhibitor (BGJ398) treatment reduced SS tumour cell growth in vitro and in vivo [92].